Ascorbic Acid Treatment in CMT1A Trial.
- Conditions
- Charcot-Marie-Tooth Disease Type 1A (CMT1A) orHereditary Motor and Sensory Neuropathies (HMSN Ia)
- Registration Number
- NL-OMON26033
- Lead Sponsor
- Department of Neurology Academic Medical Center, University of AmsterdamP.O.Box 22660Amsterdam, Netherlands
- Brief Summary
Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, Robaglia-Schlupp A, Pellissier JF, Fontes M. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease. Nat Med. 2004 Apr;10(4):396-401. Epub 2004 Mar 21. : 15034573; <br><br> Verhamme C, van Schaik IN, Koelman JH, de Haan RJ, Vermeulen M, de Visser M. Clinical disease severity and axonal dysfunction in hereditary motor and sensory neuropathy Ia. J Neurol. 2004 Dec;251(12):1491-7. : 15645349.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 12
1. DNA-proven CMT1A patients;
2. Age 12-25 years;
1. Due to possible influence on severity of the neuropathy:
a. Known other disease that may cause a neuropathy, that may decrease mobility, or that may lead to severe disability or death in a short time;
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method